You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

  • Technology appraisal guidance
  • Reference number: TA218
  • Published:  23 March 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Myelodysplastic syndromes - azacitidine: response to consultee, commentator and public comments on the ACD and comments from website consultation

Myelodysplastic syndromes - azacitidine: response to consultee, commentator and public comments on the ACD and comments from website consultation
Myelodysplastic syndromes - azacitidine: response to consultee, commentator and public comments on the ACD and comments from website consultation
17 February 2011
(88.94 Kb 25 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 16 February 2011

Back to top